- Home
- REFI vs FDMT Comparison
REFI vs FDMT Comparison
Compare REFI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- FDMT
- Stock Information
- Founded
- REFI 2021
- FDMT 2013
- Country
- REFI United States
- FDMT United States
- Employees
- REFI N/A
- FDMT N/A
- Industry
- REFI Real Estate Investment Trusts
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- FDMT Health Care
- Exchange
- REFI Nasdaq
- FDMT Nasdaq
- Market Cap
- REFI 306.1M
- FDMT 268.6M
- IPO Year
- REFI 2021
- FDMT 2020
- Fundamental
- Price
- REFI $15.24
- FDMT $4.79
- Analyst Decision
- REFI Strong Buy
- FDMT Buy
- Analyst Count
- REFI 3
- FDMT 11
- Target Price
- REFI $20.00
- FDMT $41.70
- AVG Volume (30 Days)
- REFI 172.6K
- FDMT 784.2K
- Earning Date
- REFI 03-11-2025
- FDMT 02-27-2025
- Dividend Yield
- REFI 13.53%
- FDMT N/A
- EPS Growth
- REFI N/A
- FDMT N/A
- EPS
- REFI 2.00
- FDMT N/A
- Revenue
- REFI $56,860,278.00
- FDMT $17,000.00
- Revenue This Year
- REFI N/A
- FDMT N/A
- Revenue Next Year
- REFI $6.40
- FDMT $159.49
- P/E Ratio
- REFI $7.62
- FDMT N/A
- Revenue Growth
- REFI 6.49
- FDMT N/A
- 52 Week Low
- REFI $14.82
- FDMT $4.43
- 52 Week High
- REFI $16.49
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- REFI 37.45
- FDMT 36.61
- Support Level
- REFI $15.01
- FDMT $4.43
- Resistance Level
- REFI $15.84
- FDMT $5.15
- Average True Range (ATR)
- REFI 0.20
- FDMT 0.39
- MACD
- REFI -0.01
- FDMT 0.01
- Stochastic Oscillator
- REFI 20.48
- FDMT 16.99
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.